Planned sale

Merck (MRK): Officer filed to sell ~$1.35M

CHIRFI GUINDO, Officer at Merck, filed to sell ~$1.35M of Merck shares.

~$1.35M
planned to sell · 10K shares, around Aug 13, 2026
Planned for
Aug 13, 2026
Notice filed
Aug 13, 2026

What stands out in this filing

  • The planned sale is less than 0.01% of the company's shares outstanding.
  • How the shares were acquired, per the notice: Restricted Stock Vesting Under a Registered Plan.
  • The notice says the shares were received as pay (stock awards or options).
  • Broker named on the notice: Morgan Stanley Smith Barney LLC Executive Financial Services.
  • A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 9 days earlier (Aug 4, 2026). The first one after it: changed a top executive or board member, 57 days later (Oct 9, 2026).

  1. CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  2. Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  3. Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  4. FDAFDA drug approval: Keytruda
  5. FDAFDA drug approval: Keytruda Qlex
  6. FDAFDA drug approval: Keytruda
  7. FDAFDA drug approval: Keytruda Qlex
  8. Company filing · Form 8-K · ResultsReported its results
  9. Insider · 2 peopleInsiders: 6 sales (~$9.2M)
  10. Insider · 2 peopleInsiders: 4 sales (~$2.8M)
  11. InsiderOfficer sold ~$2.71M of MRK shares in the open market
  12. Insider · 1 personInsiders: 2 sales (~$1.7M)
  13. Insider · 2 peopleInsiders: 3 sales (~$12.3M)
  14. InsiderOfficer sold ~$1.35M of MRK shares in the open market

What came next

  1. Congress · 1 personMembers of Congress: 2 purchases
  2. Federal contract · $1.6M obligatedDepartment of Health and Human Services awarded Merck: $1.63M obligated to date
  3. FDAFDA drug approval: Winrevair
  4. FDAFDA drug approval: Welireg
  5. Federal contract · $21K obligatedDepartment of Veterans Affairs awarded Merck: $21K obligated to date
  6. CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  7. Company filing · Form 8-K · Executive changeChanged a top executive or board member“(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026.”
  8. FDAFDA drug approval: Enflonsia
  9. FDAFDA drug approval: Keytruda
  10. FDAFDA drug approval: Keytruda Qlex
  11. Company filing · Form 8-K · ResultsReported its results
  12. Insider · 6 days before an 8-KOfficer sold ~$8.61M of MRK shares in the open market
  13. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 16, 2026 , Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders.”
View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Merck

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

How this filing works

Explore the data

Common questions

Which Merck (MRK) insider traded, and how much?

CHIRFI GUINDO, Officer at Merck, filed to sell ~$1.35M of Merck shares. 10K shares, Form 144 notice of a planned sale.

When did it happen, and when was it made public?

Planned for: Aug 13, 2026. Notice filed: Aug 13, 2026.

What stands out in this filing?

The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Restricted Stock Vesting Under a Registered Plan. The notice says the shares were received as pay (stock awards or options).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Merck recently?

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days. They are listed on the MRK page.

Does this mean MRK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data